WAVE Life Sciences (WVE) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls 1% as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
RBC Capital on WAVE Life Sciences (WVE): 'We appreciate the progress but remain cautious'
March 6, 2024 4:18 PM ESTRBC Capital analyst Luca Issi reiterated a Sector Perform rating and $5.00 price target on WAVE Life Sciences (NASDAQ: WVE).
The analyst comments "Next data is HD in Q2 and 20% allele specific KD is the bogey for a go/no-go decision and TAK... More
